Paul Beavis
Assoc. Prof. Beavis completed his PhD at Imperial College London in 2010 and joined Peter Mac shortly thereafter to work in the Cancer Immunology Program. He formed an independent research group in 2018, where his team is focused on the development of novel cancer immunotherapies. His team consists of three post-doctoral researchers, 2 research assistants and six PhD students.
His team has a significant interest in developing novel CAR T cell technology to enhance their effectiveness in solid cancer, guided by the philosophy that engagement of host immunity is key for effective responses. Their work has been published in leading journals including Nature Immunology, The Journal of Clinical Investigation and Nature Communications. He is a fundamental cancer researcher and immunologist but his work has a strong translational focus and his collaborative research studies with industry partners and clinicians have provided the foundation for clinical application of his work.
Paul holds a Mid-Career Fellowship from the Victorian Cancer Agency and his work is supported by funding from NHMRC, Cancer Australia, NBCF and Cancer Council Victoria.
Abstracts this author is presenting: